INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201

RTTNews | 852 일 전
INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201

(RTTNews) - Biotechnology company INOVIO Pharmaceuticals, Inc. (INO) announced Thursday positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.

In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants.

INO-4201 was evaluated in a 46-participant randomized, placebo-controlled Phase 1b trial (NCT04906629) to assess its safety, tolerability, and immunogenicity in healthy adult participants who previously received a single injection of Ervebo, a vaccine approved by the U.S. Food and Drug Administration for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.

The participants were dosed with 1 mg of INO-4201 injected intradermally followed by electroporation using our investigational proprietary smart device, CELLECTRA. The trial was designed to test whether INO-4201 can be used as a booster in healthy participants previously vaccinated with Ervebo.

For More Such Health News, visit rttnews.com

read more
Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP

Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP

Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Tuesday that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program.
RTTNews | 602 일 전
FTSE 100 Up Marginally In Cautious Trade

FTSE 100 Up Marginally In Cautious Trade

After edging up a bit in early trades, the U.K. stock market drifted lower Tuesday morning, but edged up on selective buying and was up marginally nearly half an hour past noon. A downward revision in UK's growth forecast by OECD, and uncertainty surrounding the U.S. Government's tariff moves weigh on sentiment. The OECD has also downgraded its global growth forecast.
RTTNews | 59 분 전
Euro Area Jobless Rate Eases To 6.2% As Expected

Euro Area Jobless Rate Eases To 6.2% As Expected

Eurozone unemployment rate fell for the first time in four months in April, in line with expectations, preliminary data from the statistical office Eurostat showed on Tuesday.
RTTNews | 1 시간 20 분 전
CAC 40 Down Marginally In Lackluster Trade

CAC 40 Down Marginally In Lackluster Trade

French stocks are down on Tuesday, extending recent losses, as a downgrade revision in global growth forecast by the Organization for Economic Co-operation and Development (OECD), and continued uncertainty about Trump administration's tariff moves weigh on sentiment.
RTTNews | 1 시간 35 분 전
German Stocks Up Marginally After Mild Setback

German Stocks Up Marginally After Mild Setback

The German market, which retreated after a positive start Tuesday morning, recovered some lost ground subsequently, but remains a bit subdued, amid concerns about global economic growth due to Trump administration's uncertain trade policies. A downward revision in global growth forecast by OECD, and news about the collapse of the Deutsche Government are weighing on sentiment.
RTTNews | 1 시간 58 분 전